- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Oxford Nanopore Tech - Participation in upcoming investor conferences | 1 | RNS | ||
| 02.11. | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | 4 | RNS | ||
| 20.10. | IN BRIEF: Oxford Nanopore Technologies hires US executive from Philips | 13 | Alliance News | ||
| 20.10. | Oxford Nanopore Tech - Appointment of Chief Business Development Officer | - | RNS | ||
| OXFORD NANOPORE TECHNOLOGIES PLC ADR Aktie jetzt für 0€ handeln | |||||
| 14.10. | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | - | RNS | ||
| 12.10. | Oxford Nanopore Tech - Director/PDMR Shareholding | 12 | RNS | ||
| 02.10. | IP Group sells down stake in Oxford Nanopore | 25 | Sharecast | ||
| 02.10. | IP Group veräußert Oxford Nanopore-Anteile im Wert von 21 Millionen Pfund | 23 | Investing.com Deutsch | ||
| 02.10. | IP Group completes £21m partial sale of Oxford Nanopore stake | 4 | Investing.com | ||
| 02.10. | Oxford Nanopore Tech - Holding(s) in Company | 3 | RNS | ||
| 01.10. | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | 1 | RNS | ||
| 25.09. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.09.2026 | 473 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.09.2026
Aktien
1 US69166E1047 Oxford Nanopore Technologies... ► Artikel lesen | |
| 16.09. | Oxford Nanopore Wins Preliminary Injunction Against MGI Tech Over Cyclone Sequencing Systems | 3 | RTTNews | ||
| 16.09. | Oxford Nanopore wins injunction against MGI Tech in patent case | 4 | Investing.com | ||
| 16.09. | Patentrechtsstreit: Oxford Nanopore erwirkt einstweilige Verfügung gegen MGI Tech | 11 | Investing.com Deutsch | ||
| 16.09. | Oxford Nanopore Tech - Preliminary injunction against MGI Tech GmbH | - | RNS | ||
| 14.09. | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | - | RNS | ||
| 09.09. | Oxford Nanopore Tech - Participation in upcoming investor conferences | - | RNS | ||
| 04.09. | FTSE 250 movers: Oxford Nanopore, Rosebank in the red | 3 | Sharecast | ||
| 04.09. | Director dealings: Oxford Nanopore CFO raises stake | 13 | Sharecast |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
OXFORD NANOPORE TECHNOLOGIES PLC ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,44 % bei einem Aktienkurs von 9,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OXFORD NANOPORE TECHNOLOGIES PLC ADR finden Sie auf Wallstreet Online.